Huntington’s Disease Treatment Market Outlook
According to Renub Research, the global Huntington’s disease treatment market is projected to reach USD 1,284.69 million by 2030. Huntington’s disease is a rare genetic condition that leads to the progressive degeneration of brain nerve cells, causing significant motor, cognitive, and psychiatric symptoms. Although it usually manifests in a person’s 30s or 40s, the rate of symptom onset can vary. Early warning signs often include mood changes and abnormal behavior, with later stages affecting motor skills and cognitive function.
The growing number of cases among the geriatric population and the resulting increase in medical research and development are driving the Huntington’s disease treatment market. The surge in cases of depression, which is an early symptom of Huntington’s disease, is expected to further fuel market growth. Strategic mergers and acquisitions among key market players are also driving market expansion.
Huntington’s Disease Treatment Market Expected to Grow at a CAGR of 16.53% from 2022 to 2030
Huntington’s disease affects approximately 1 in 10,000 individuals, with 36 to 200 CAG repeats in the Huntingtin (Htt) gene, compared to fewer than 35 in healthy individuals. The regional disparities in Huntington’s disease occurrence result in a tenfold variation. Immunomodulatory drugs targeting the hyperactive immune response in Huntington’s disease are gaining traction. Ingrezza’s label expansion for chorea associated with Huntington’s disease, the high prevalence of Huntington’s disease in Western countries, and a robust pipeline of disease-modifying treatments are expected to contribute to the market’s growth.
Request for free Sample Report: https://www.renub.com/request-sample-page.php?gturl=huntington-disease-treatment-market-p.php
The U.S. Centers for Disease Control and Prevention (CDC) reports that approximately 30,000 people in the U.S. are affected by Huntington’s disease. In Europe, it affects up to 10 per 100,000 individuals. Research into cell and gene-based therapies, neurogenesis, neuron regeneration, and methods to reduce Huntingtin protein production is underway. The global Huntington’s disease treatment market was valued at USD 377.73 million in 2022.
Approved Drugs Expected to Dominate the Huntington’s Disease Treatment Market
By drug type, the Huntington’s disease treatment market is segmented into approved drugs and off-label drugs. Approved drugs are anticipated to lead the market due to their proven effectiveness in managing Huntington’s disease symptoms and their regulatory compliance. These drugs offer a reliable option for physicians and patients in managing the complex symptoms associated with the condition.
Drug Stores and Retail Pharmacies are Rapidly Growing Segments in the Huntington’s Disease Treatment Market
By end-user, the market is segmented into hospital pharmacies, drug stores, retail pharmacies, and online pharmacies. Drug stores and retail pharmacies are the fastest-growing segments due to their convenience and accessibility. As more individuals seek treatment for Huntington’s disease, these pharmacies offer a readily available source for obtaining medications, contributing to the segment’s rapid growth.
United States Expected to Maintain Its Lead in the Huntington’s Disease Treatment Market
By country, the Huntington’s disease treatment market is divided into the United States, Canada, Germany, the United Kingdom, France, Italy, the Netherlands, Spain, China, South Korea, Japan, India, Indonesia, Malaysia, Argentina, Brazil, Mexico, Colombia, Saudi Arabia, South Africa, Israel, Australia, UAE, and the Rest of the World. The United States holds the largest market share due to its robust healthcare infrastructure, high prevalence of Huntington’s disease, and significant research and development activities. The U.S. pharmaceutical industry is also a global leader in drug development, solidifying the country’s top position in the Huntington’s disease treatment market.
Key Players in the Huntington’s Disease Treatment Market
Major companies in the Huntington’s disease treatment market include H. Lundbeck, Pfizer Inc., Bausch Health Companies, Teva Pharmaceutical Industries, Dr. Reddy’s Laboratories, Sun Pharmaceutical Industries Limited, Hikma Pharmaceuticals Plc, Alnylam Pharmaceuticals, Novartis AG, and UniQure.
Recent Developments
These developments highlight the ongoing innovation and strategic expansion within the Huntington’s disease treatment market, contributing to the growing market value and enhanced treatment options for Huntington’s disease.
Renub Research is a Market Research and Information Analysis company with more than 15 years of experience in Research, Survey, and Consulting. Our research helps companies to take business decisions: on strategy, organization, operations, technology, mergers & acquisitions, etc. Till now we have published more than 9000 syndicated reports and worked on more than 750 custom research projects. Currently, we are supplying data to EMIS, Bloomberg, Thomson Reuters, etc. We support many blue-chip companies by providing them with findings and perspectives across a wide range of markets.
Company Name: Renub Research
Contact Person: Rajat Gupta, Marketing Manager
Phone No: +1-478-202-3244 | +91-120-421-9822 (IND)
Address: 225 Kristie Ln, Roswell, GA 30076
Email: info@renub.com
LinkedIn: https://linkedin.com/company/renub-research
Website: www.renub.com
